Functional Endoscopic Sinus Surgery (FESS) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Functional Endoscopic Sinus Surgery (FESS) is a minimally invasive surgical technique used to treat chronic sinusitis, nasal polyps, and other sinus-related conditions that have failed to respond to medical therapy. The procedure uses rigid nasal endoscopes — thin telescopes with fiber-optic lighting — inserted through the nostrils to visualize and surgically open the natural drainage pathways (ostia) of the paranasal sinuses. Unlike traditional sinus surgery, FESS avoids external incisions and focuses on restoring normal sinus ventilation and mucociliary clearance.

Chronic rhinosinusitis (CRS) is one of the most prevalent chronic diseases worldwide, affecting approximately 12% of the adult population in the United States and 5–15% globally. The condition significantly impacts quality of life, causing facial pain, nasal congestion, postnasal drip, anosmia, and fatigue. When symptoms persist for 12 weeks or longer despite appropriate medical management — including nasal corticosteroid sprays, saline irrigations, and antibiotics — surgical intervention with FESS is recommended. Approximately 600,000 FESS procedures are performed annually in the United States alone.

First introduced by Messerklinger in the 1970s and popularized by Stammberger and Kennedy in the 1980s, FESS revolutionized sinus surgery by shifting from radical, tissue-destructive approaches to targeted, function-preserving techniques. Modern FESS incorporates advanced technologies including image-guided navigation (IGN), powered microdebriders, balloon sinuplasty, and high-definition endoscopic cameras. These innovations have improved surgical precision, reduced complication rates, and expanded the range of pathology that can be safely addressed through the nostrils.

FESS is indicated for a variety of sinonasal conditions that have not adequately responded to medical therapy. The primary indications include:

• Chronic rhinosinusitis (CRS) — persistent sinus inflammation lasting 12+ weeks, both with and without nasal polyps (CRSwNP and CRSsNP)
• Nasal polyposis — benign mucosal growths within the nasal cavity and sinuses causing obstruction and anosmia
• Recurrent acute sinusitis — four or more episodes of acute bacterial sinusitis per year despite prophylactic measures
• Allergic fungal rhinosinusitis (AFRS) — eosinophilic mucin with fungal elements causing chronic sinus disease
• Mucocele — mucus-filled cysts expanding within the sinuses, causing pressure on surrounding structures
• Sinus tumors — benign tumors such as inverted papilloma requiring endoscopic resection
• CSF leak repair — cerebrospinal fluid leaks from the anterior skull base approachable through the nose
• Orbital decompression — for Graves' ophthalmopathy or orbital abscess secondary to sinusitis
• Dacryocystorhinostomy (DCR) — endoscopic approach for blocked tear duct surgery

The procedure may also be used as an adjunct in managing aspirin-exacerbated respiratory disease (Samter's triad), cystic fibrosis-related sinusitis, and to improve access for topical medication delivery in patients with narrowed sinus openings.

The ideal candidate for FESS is an adult patient with documented chronic rhinosinusitis that has persisted despite a minimum of 8–12 weeks of maximal medical therapy. This medical therapy should include intranasal corticosteroid sprays, regular saline nasal irrigations, and at least one course of appropriate antibiotics. CT imaging of the sinuses (the gold standard for surgical planning) must demonstrate objective evidence of sinus disease corresponding to the patient's symptoms. Patients should have realistic expectations about outcomes and be committed to postoperative care including nasal irrigations and follow-up visits.

Relative contraindications include uncontrolled bleeding disorders, severe medical comorbidities that preclude general anesthesia, and active cocaine abuse causing nasal tissue damage. Patients taking anticoagulants or antiplatelet medications may require temporary cessation before surgery. Caution is exercised in patients with previous sinus surgery (revision FESS carries higher complication risks), those with extensive skull base defects, and patients with Samter's triad who have high polyp recurrence rates. Pediatric patients may be candidates for FESS, though adenoidectomy and continued medical management are typically attempted first.

Pre-surgical assessment includes nasal endoscopy, CT scanning of the paranasal sinuses (coronal and axial views), allergy testing if not previously performed, and assessment for associated conditions such as asthma. Image-guided navigation is planned when anatomy is complex, when revision surgery is required, or when disease extends near critical structures such as the orbit, optic nerve, or anterior skull base. Patients are typically counseled that FESS improves but rarely cures chronic sinusitis, and ongoing medical management remains essential after surgery.

FESS encompasses a spectrum of procedures tailored to the extent and location of disease. Uncinectomy and maxillary antrostomy involve removing the uncinate process and widening the natural maxillary sinus ostium to restore drainage — this is the most commonly performed FESS procedure. Anterior ethmoidectomy opens the anterior ethmoid air cells, while posterior ethmoidectomy extends to the posterior cells. Sphenoidotomy opens the sphenoid sinus, and frontal sinusotomy (Draf I, II, or III) addresses the frontal sinus outflow tract, with the Draf III (modified Lothrop or endoscopic frontal drillout) being the most extensive approach for refractory frontal sinus disease.

Several adjunctive technologies enhance FESS outcomes. Image-guided navigation (IGN) uses preoperative CT data to provide real-time three-dimensional tracking of instruments within the sinuses, improving safety near critical structures such as the orbit, optic nerve, and skull base. Powered microdebriders provide controlled tissue removal with simultaneous suction, reducing operative time and improving hemostasis. Balloon sinuplasty offers a tissue-preserving option that dilates sinus openings using catheter-mounted balloons without removing bone or mucosa, suitable for limited disease in select patients.

Extended endoscopic approaches have expanded FESS beyond traditional sinusitis treatment. Endoscopic skull base surgery can address pituitary tumors, anterior cranial fossa meningiomas, CSF leaks, and sinonasal malignancies through the nostrils. These advanced procedures are performed by multidisciplinary teams including otolaryngologists and neurosurgeons. For patients with extensive nasal polyposis, polypectomy with microdebrider combined with thorough ethmoidectomy and postoperative biologic therapy (dupilumab, omalizumab, or mepolizumab) has shown significantly improved polyp recurrence rates compared to surgery alone.

FESS demonstrates excellent outcomes for chronic sinusitis treatment, with 80–95% of patients reporting significant symptom improvement. Multiple large meta-analyses confirm that FESS reduces nasal obstruction scores by 60–75%, facial pain by 65–80%, and postnasal drip by 55–70%. Olfactory function improves in 50–70% of patients, particularly those with nasal polyposis. Quality of life scores (measured by validated instruments such as the SNOT-22) improve by an average of 30–40 points postoperatively, representing clinically meaningful gains.

Compared to traditional open sinus surgery, FESS offers substantial advantages including no external incisions or scarring, reduced postoperative pain, shorter hospital stays (most patients go home the same day), faster recovery with return to work within 1–2 weeks, and lower complication rates. The procedure preserves normal sinus mucosa and function rather than stripping it, promoting better long-term physiological outcomes. Additionally, FESS improves the delivery of topical medications (corticosteroid irrigations) by creating wider sinus openings, which is critical for ongoing medical management.

Long-term studies with 5–10 year follow-up show that approximately 75–85% of patients maintain symptom improvement after FESS. Revision surgery is needed in approximately 10–20% of cases, with higher revision rates in patients with nasal polyps, aspirin sensitivity, cystic fibrosis, or allergic fungal sinusitis. The combination of FESS with appropriate postoperative medical therapy and regular nasal irrigations yields the best long-term outcomes. For patients with asthma and concomitant CRS, FESS has been shown to improve asthma control, reduce asthma medication requirements, and decrease asthma-related hospitalizations.

FESS is generally safe with an overall major complication rate of less than 1%. Minor complications occur in 5–10% of cases and include postoperative bleeding (epistaxis) requiring nasal packing (3–5%), synechia (adhesion) formation between mucosal surfaces (5–8%), and temporary periorbital ecchymosis (bruising around the eyes). Minor bleeding during the first 1–2 weeks is common and usually self-limiting with head elevation and nasal decongestants. Crusting within the sinuses is expected during healing and managed with saline irrigations.

Major complications are rare but include orbital injury (0.1–0.5%), presenting as orbital hematoma, extraocular muscle injury, or visual impairment — orbital hematoma is a surgical emergency requiring immediate lateral canthotomy. Cerebrospinal fluid (CSF) leak from skull base injury occurs in 0.1–0.5% of cases and may require intraoperative or postoperative repair. Severe hemorrhage from injury to the anterior ethmoid artery, sphenopalatine artery, or internal carotid artery (extremely rare, less than 0.1%) can be life-threatening. Anosmia (permanent loss of smell) occurs in less than 1% of cases.

Risk factors for complications include revision surgery (where scarring and distorted anatomy increase complexity), extensive polyposis, skull base dehiscence, and anatomical variants such as Onodi cells (placing the optic nerve at risk) or asymmetric skull base. The use of image-guided navigation has been shown to reduce complication rates in complex cases. Postoperative complications include sinus infection during the healing period, frontal sinus stenosis requiring additional procedures, and recurrence of polyps — which is a disease recurrence rather than a surgical complication. Patients should be aware that smoking significantly increases complication risk and polyp recurrence.

Most FESS procedures are performed as same-day (outpatient) surgery, with patients discharged several hours after the procedure. Nasal packing, if used, is typically absorbable and dissolves over 1–2 weeks, or removable packing is taken out at the first postoperative visit within 3–7 days. Patients experience nasal congestion, mild facial pressure, and blood-tinged nasal discharge for 1–2 weeks. Pain is generally mild to moderate and well-controlled with acetaminophen; NSAIDs are typically avoided initially due to bleeding risk.

Postoperative care involves regular high-volume saline nasal irrigations (beginning 24–48 hours after surgery), which are critical for removing crusts, promoting healing, and preventing adhesion formation. Patients should avoid nose blowing, heavy lifting, strenuous exercise, and bending forward for 1–2 weeks. Most patients return to desk work within 5–7 days and resume full activities by 2–3 weeks. Postoperative endoscopic debridement — performed in the office at 1 week, 3 weeks, and 6 weeks — removes crusts, early scar tissue, and residual disease, and is essential for optimal outcomes.

Long-term follow-up typically includes visits at 3 months, 6 months, and 12 months postoperatively, with annual evaluations thereafter for patients with polyps or recurrent disease. Ongoing medical therapy is the cornerstone of sustained improvement and includes daily nasal saline irrigations (often with budesonide or mometasone added), intranasal corticosteroid sprays, and allergen avoidance. For patients with recurrent polyposis, biologic medications (dupilumab, omalizumab, mepolizumab) may be initiated postoperatively to reduce recurrence rates. Patients should be counseled that FESS opens and restores sinus drainage pathways, but the underlying inflammatory condition requires lifelong management.

The cost of FESS varies significantly based on the extent of surgery, geographic location, facility type, and surgeon expertise. In the United States, the average cost ranges from $8,000 to $20,000 including surgeon fees, anesthesia, and facility charges. Simple unilateral procedures cost less, while bilateral comprehensive FESS with image-guided navigation and septoplasty can reach $15,000–$25,000. These costs do not include preoperative CT imaging ($200–$500), allergy testing ($200–$1,000), or postoperative debridement visits.

Key cost variables include the number of sinuses addressed (unilateral vs. bilateral, limited vs. complete), use of image-guided navigation (adds $1,000–$3,000), balloon sinuplasty instrumentation, concurrent procedures (septoplasty, turbinate reduction, polyp removal), type of nasal packing used, and whether the procedure is performed in a hospital versus ambulatory surgery center. Revision FESS is typically more expensive than primary surgery due to increased complexity and longer operative time.

Health insurance typically covers FESS when medical necessity criteria are met, including documentation of failed maximum medical therapy, CT evidence of sinus disease, and supporting nasal endoscopy findings. Patients should expect co-pays, deductibles, and potentially coinsurance. For medical tourism patients, FESS is available at significantly reduced costs in India ($1,500–$4,000), Thailand ($2,500–$5,000), Turkey ($2,000–$4,500), and Mexico ($2,000–$5,000), with many centers offering experienced ENT surgeons and modern endoscopic equipment. Preauthorization is typically required, and patients should verify that postoperative debridement visits are included in the surgical package.

Continued medical therapy remains an alternative for patients who are not surgical candidates or prefer conservative management. This includes high-volume saline irrigations with budesonide, intranasal corticosteroid sprays, short courses of oral corticosteroids for polyp disease, long-term macrolide antibiotics (low-dose azithromycin or clarithromycin for their anti-inflammatory properties), and leukotriene receptor antagonists. Approximately 50% of chronic sinusitis patients can be adequately managed with medical therapy alone, avoiding surgery.

Balloon sinuplasty is a less invasive office-based alternative for patients with limited sinus disease, particularly isolated maxillary, frontal, or sphenoid sinus involvement without extensive polyps. The procedure dilates sinus ostia using balloon catheters under local anesthesia without tissue removal. While effective for select patients (80–90% symptom improvement for appropriate candidates), it is not suitable for patients with extensive polyposis, fungal sinusitis, or ethmoid-predominant disease. Recovery is faster, with most patients returning to normal activities within 24–48 hours.

Biologic therapies represent an emerging non-surgical alternative for CRS with nasal polyps. Dupilumab (anti-IL-4/IL-13), omalizumab (anti-IgE), and mepolizumab (anti-IL-5) have demonstrated significant polyp size reduction, improved olfaction, and reduced need for surgery in randomized controlled trials. However, these medications require ongoing subcutaneous injections, are expensive ($15,000–$40,000 annually), and may not eliminate the need for surgery in severe cases. Aspirin desensitization therapy may benefit patients with aspirin-exacerbated respiratory disease. Immunotherapy (allergy shots or sublingual tablets) addresses the allergic component of CRS and can reduce symptom severity and recurrence rates when allergic rhinitis is a significant contributing factor.